NCT02098330

Brief Summary

The purpose of this study was to compare the treatment effectiveness of steroid therapy for vestibular neuritis by using video head impulse test.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at below P25 for phase_3

Timeline
Completed

Started Mar 2014

Shorter than P25 for phase_3

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2014

Completed
20 days until next milestone

First Submitted

Initial submission to the registry

March 21, 2014

Completed
7 days until next milestone

First Posted

Study publicly available on registry

March 28, 2014

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2014

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2015

Completed
Last Updated

January 10, 2019

Status Verified

January 1, 2019

Enrollment Period

9 months

First QC Date

March 21, 2014

Last Update Submit

January 8, 2019

Conditions

Keywords

Vestibular neuritisVertigoHead impulse testSteroid

Outcome Measures

Primary Outcomes (1)

  • The improvement in vestibular function test (caloric & videop HIT) after treatment

    The effectiveness of steroid therapy was determined by comparing the improvement of vestibular function (the degree of canal paresis by caloric test; gain and presence of refixation-saccade by video HIT test).

    The first results were collected at initial diagnosis. And following results were collected 6 months after the first exam.

Secondary Outcomes (1)

  • The improvement in dizziness handicap inventory after treatment

    The first results were collected at initial diagnosis. And following results were collected 6 months after the first exam.

Study Arms (2)

: Ginkgo biloba & methylprednisolone

ACTIVE COMPARATOR

Patients receive Ginkgo biloba \& methylprednisolone per oral.

Drug: Ginkgo biloba & Methylprednisolone

Ginkgo biloba

PLACEBO COMPARATOR

Patients receive Ginkgo biloba per oral.

Drug: Ginkgo biloba

Interventions

Ginkgo biloba 160 mg/day (per oral, 80 mg twice a day) for 1 month. Methylprednisolone 48 mg/day(per oral, once a day for first 9 days. And then methylprednisolone tapering was started every 2 days. The entire duration of methylprednisolone treatment was 14 days.

Also known as: Ginexin, Methylprednisolone
: Ginkgo biloba & methylprednisolone

Ginkgo biloba 160 mg/day (per oral, 80 mg twice a day) for 1 month.

Also known as: Ginexin
Ginkgo biloba

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Ages over 18 years
  • Acute vertigo that occurred within 7 days
  • The spontaneous nystagmus should be detected
  • Caloric weakness over 20%

You may not qualify if:

  • Suspicious or verified a central nervous system lesion
  • If the patient has denied.
  • Other otologic disease (acute/chronic otitis media, otosclerosis, etc)
  • The patient with history of otologic surgery
  • The patient with history of brain surgery

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Asan Medical Center

Seoul, Songpa-gu, 138-736, South Korea

Location

Related Publications (1)

  • Yoo MH, Yang CJ, Kim SA, Park MJ, Ahn JH, Chung JW, Park HJ. Efficacy of steroid therapy based on symptomatic and functional improvement in patients with vestibular neuritis: a prospective randomized controlled trial. Eur Arch Otorhinolaryngol. 2017 Jun;274(6):2443-2451. doi: 10.1007/s00405-017-4556-1. Epub 2017 Apr 8.

MeSH Terms

Conditions

Vestibular NeuronitisVertigo

Interventions

Ginkgo ExtractMethylprednisolone

Condition Hierarchy (Ancestors)

Vestibulocochlear Nerve DiseasesRetrocochlear DiseasesEar DiseasesOtorhinolaryngologic DiseasesCranial Nerve DiseasesNervous System DiseasesVestibular DiseasesLabyrinth DiseasesNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Plant ExtractsPlant PreparationsBiological ProductsComplex MixturesPrednisolonePregnadienetriolsPregnadienesPregnanesSteroidsFused-Ring CompoundsPolycyclic Compounds

Study Officials

  • Hong Ju Park, Professor

    Asan Medical Center

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

March 21, 2014

First Posted

March 28, 2014

Study Start

March 1, 2014

Primary Completion

December 1, 2014

Study Completion

June 1, 2015

Last Updated

January 10, 2019

Record last verified: 2019-01

Locations